Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia.

EJHaem · 2023 · PMC10188504 · PMID 37206255

Europe PMC DOI

hedged sentence

0.0930

closest p · 1.9× alpha

0.0930

boldest claim

The sentences

approaching significancep = 0.093so close (0.05 < p ≤ 0.1)

Deaths within 30 and 60 days were non‐significantly higher in the azacitidine‐venetoclax cohort compared to decitabine‐venetoclax, with more deaths within 60 days in the azacitidine‐venetoclax cohort approaching significance ( p = 0.093).

also in 1,619 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.